pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 43 Non-oncology: 30
Oncology: 13
Under Consideration for Negotiation 17 Non-oncology: 12
Oncology: 5
Completed Negotiations 738 With Letter of Intent: 635
Without agreement: 103
Negotiations That Were Not Pursued 108

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Axberi/Axberi HP Baxter Corporation Thrombosis and cardiovascular conditions (prevention or treatment)
Velsipity Pfizer Canada ULC Ulcerative Colitis
Ixifi Pfizer Canada ULC Multiple Indications
Truqap AstraZeneca Canada Inc. Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative)
Tavneos Otsuka Canada Pharmaceutical Inc. Antineutrophil cytoplasmic antibody-associated vasculitis
Apretude ViiV Healthcare HIV-1 infection, pre-exposure prophylaxis
Myalepta Medison Pharma Canada Inc. Leptin deficiency in lipodystrophy

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Tecentriq SC Hoffmann-La Roche Ltd. Multiple Indications
Koselugo Alexion Pharma GmbH Neurofibromatosis type 1 in pediatric patients aged 2 years and above, who have symptomatic, inoperable plexiform neurofibromas
Keytruda Merck Canada Inc. In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinom
Trecondyv Medexus Pharmaceuticals, Inc. As part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies (In combination with fludarabine)
Trikafta Vertex Pharmaceuticals (Canada) Incorporated Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older
Akeega Janssen Inc. Deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC) in adult patients who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated. (in combin
Eylea HD Bayer Inc. Age-Related Macular Degeneration
Eylea HD Bayer Inc. Diabetic Macular Edema
Verzenio Eli Lilly Canada Inc. ​In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Pluvicto Advanced Accelerator Applications Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks